Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
GHDX's Cash to Debt is ranked higher than
88% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.82 vs. GHDX: No Debt )
GHDX' s 10-Year Cash to Debt Range
Min: 4.9   Max: No Debt
Current: No Debt

Equity to Asset 0.80
GHDX's Equity to Asset is ranked higher than
87% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.64 vs. GHDX: 0.80 )
GHDX' s 10-Year Equity to Asset Range
Min: -3.56   Max: 0.89
Current: 0.8

-3.56
0.89
Interest Coverage No Debt
GHDX's Interest Coverage is ranked higher than
87% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 94.07 vs. GHDX: No Debt )
GHDX' s 10-Year Interest Coverage Range
Min: 80.08   Max: 9999.99
Current: No Debt

80.08
9999.99
F-Score: 4
Z-Score: 17.60
M-Score: -2.74
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -9.49
GHDX's Operating margin (%) is ranked higher than
68% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.61 vs. GHDX: -9.49 )
GHDX' s 10-Year Operating margin (%) Range
Min: -12348   Max: 4.01
Current: -9.49

-12348
4.01
Net-margin (%) -10.06
GHDX's Net-margin (%) is ranked higher than
67% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. GHDX: -10.06 )
GHDX' s 10-Year Net-margin (%) Range
Min: -12200   Max: 3.81
Current: -10.06

-12200
3.81
ROE (%) -19.30
GHDX's ROE (%) is ranked higher than
63% of the 233 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. GHDX: -19.30 )
GHDX' s 10-Year ROE (%) Range
Min: -1865.06   Max: 7.79
Current: -19.3

-1865.06
7.79
ROA (%) -15.66
GHDX's ROA (%) is ranked higher than
64% of the 261 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. GHDX: -15.66 )
GHDX' s 10-Year ROA (%) Range
Min: -91.5   Max: 6.18
Current: -15.66

-91.5
6.18
ROC (Joel Greenblatt) (%) -101.51
GHDX's ROC (Joel Greenblatt) (%) is ranked higher than
64% of the 260 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.02 vs. GHDX: -101.51 )
GHDX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2388.09   Max: 74.51
Current: -101.51

-2388.09
74.51
Revenue Growth (3Y)(%) 12.60
GHDX's Revenue Growth (3Y)(%) is ranked higher than
90% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. GHDX: 12.60 )
GHDX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 136.8
Current: 12.6

0
136.8
» GHDX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

GHDX Guru Trades in Q4 2013

Paul Tudor Jones 15,100 sh (New)
Steven Cohen 14,221 sh (New)
Jim Simons 52,901 sh (+39.95%)
Chuck Royce 33,000 sh (unchged)
» More
Q1 2014

GHDX Guru Trades in Q1 2014

Jim Simons 108,555 sh (+105.2%)
Chuck Royce 33,000 sh (unchged)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
» More
Q2 2014

GHDX Guru Trades in Q2 2014

Chuck Royce 33,000 sh (unchged)
Jim Simons Sold Out
» More
Q3 2014

GHDX Guru Trades in Q3 2014

Chuck Royce 33,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with GHDX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
David Swensen 2013-03-31 Sold Out 2.8%$26.72 - $29.65 $ 32.4414%0
David Swensen 2012-12-31 New Buy2.8%$26.42 - $36.8 $ 32.448%37861
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 7.20
GHDX's P/B is ranked higher than
64% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.46 vs. GHDX: 7.20 )
GHDX' s 10-Year P/B Range
Min: 3.3   Max: 14.23
Current: 7.2

3.3
14.23
P/S 3.70
GHDX's P/S is ranked higher than
72% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.17 vs. GHDX: 3.70 )
GHDX' s 10-Year P/S Range
Min: 2.17   Max: 20.45
Current: 3.7

2.17
20.45
EV-to-EBIT -35.37
GHDX's EV-to-EBIT is ranked lower than
52% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. GHDX: -35.37 )
GHDX' s 10-Year EV-to-EBIT Range
Min: -791   Max: 514.8
Current: -35.37

-791
514.8
Current Ratio 4.32
GHDX's Current Ratio is ranked higher than
82% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. GHDX: 4.32 )
GHDX' s 10-Year Current Ratio Range
Min: 3.54   Max: 15.83
Current: 4.32

3.54
15.83
Quick Ratio 4.32
GHDX's Quick Ratio is ranked higher than
86% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. GHDX: 4.32 )
GHDX' s 10-Year Quick Ratio Range
Min: 3.54   Max: 15.83
Current: 4.32

3.54
15.83

Valuation & Return

vs
industry
vs
history
Price/Net Cash 14.95
GHDX's Price/Net Cash is ranked higher than
88% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. GHDX: 14.95 )
GHDX' s 10-Year Price/Net Cash Range
Min: 3.64   Max: 22.82
Current: 14.95

3.64
22.82
Price/Net Current Asset Value 11.15
GHDX's Price/Net Current Asset Value is ranked higher than
87% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. GHDX: 11.15 )
GHDX' s 10-Year Price/Net Current Asset Value Range
Min: 3.63   Max: 20.64
Current: 11.15

3.63
20.64
Price/Tangible Book 7.16
GHDX's Price/Tangible Book is ranked higher than
73% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.25 vs. GHDX: 7.16 )
GHDX' s 10-Year Price/Tangible Book Range
Min: 3.3   Max: 11.72
Current: 7.16

3.3
11.72
Price/DCF (Projected) 4.86
GHDX's Price/DCF (Projected) is ranked higher than
81% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. GHDX: 4.86 )
GHDX' s 10-Year Price/DCF (Projected) Range
Min: 4.17   Max: 38.47
Current: 4.86

4.17
38.47
Price/Median PS Value 0.85
GHDX's Price/Median PS Value is ranked higher than
91% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.36 vs. GHDX: 0.85 )
GHDX' s 10-Year Price/Median PS Value Range
Min: 0.53   Max: 3.65
Current: 0.85

0.53
3.65
Earnings Yield (Greenblatt) -2.80
GHDX's Earnings Yield (Greenblatt) is ranked higher than
68% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.00 vs. GHDX: -2.80 )
GHDX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 1.3
Current: -2.8

0.2
1.3

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:G7H.Germany,
Genomic Health Inc was incorporated in Delaware in August 2000. It is a healthcare company that provides actionable genomic information to personalize cancer treatment decisions. The Company is engaged in the development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The Company's Oncotype DX breast and colon tests have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment. The Company provides its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provide physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ, or DCIS and a Genomic Prostate Score, or GPS, for prostate cancer. Its Oncotype DX platform utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction, or RT-PCR, in standard tumor pathology specimens to provide tumor-specific information, or the "oncotype" of a tumor. Its Oncotype DX breast cancer test analyzes the expression levels of 21 genes and its Oncotype DX colon cancer test analyzes the expression levels of 12 genes. Its Oncotype DX prostate cancer test measures the level of expression of 17 genes across four biological pathways to predict prostate cancer aggressiveness in men with low risk disease. It has a direct commercial presence with employees and consultants in the United States and certain other countries, and its Oncotype DX breast and colon cancer tests are also available outside of the United States through a network of distributors. The Company faces competition from companies that offer products or have conducted research to profile genes, gene expression or protein expression in breast, colon or prostate cancer, including public companies such as, GE Healthcare, a business unit of General Electric Company, Hologic, Inc., Myriad Genetics, Inc., NanoString Technologies, Inc., Novartis AG, Qiagen N.V. and Response Genetics, Inc., and many private companies. It faces competition from commercial laboratories with distribution networks for diagnostic tests, such as Laboratory Corporation of America Holdings and Quest Diagnostics Incorporated. The Company holds 32 issued patents in the United States and 65 issued patents outside of the United States. As a clinical reference laboratory, the Company is subject to hold certain federal, state and local licenses, certifications and permits to conduct its business.
» More Articles for GHDX

Headlines

Articles On GuruFocus.com
CEO of InVitae Corporation of Genomic Health Inc. Randal W. Scott Sold 30,000 Shares Jul 13 2012 
Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Mar 16 2011 
Genomic Health Inc. (GHDX) CFO Dean L Schorno sells 1,000 Shares Mar 16 2011 
Genomic Health Inc. (GHDX) Executive Chairman Randal W Scott sells 20,000 Shares Mar 14 2011 
Genomic Health Inc. (GHDX) COO G Bradley Cole sells 2,500 Shares Mar 10 2011 
Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Feb 16 2011 
Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Feb 16 2011 
Genomic Health Inc. (GHDX) CFO Dean L Schorno sells 1,000 Shares Feb 16 2011 
Genomic Health Inc. (GHDX) Executive Chairman Randal W Scott sells 20,000 Shares Feb 14 2011 
Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Jan 19 2011 


More From Other Websites
Nasdaq stocks posting largest percentage decreases Dec 24 2014
Claritas Genomics Appoints Patrick F. Terry as Chief Commercial Officer Dec 18 2014
Oncotype DX® DCIS Score™ Represents Breakthrough in Personalizing Treatment of Pre-Invasive... Dec 12 2014
Oncotype DX® DCIS Score™ Represents Breakthrough in Personalizing Treatment of Pre-Invasive... Dec 12 2014
Genomic Health's Liquid Biopsy Tests Positive in Twin Studies Dec 11 2014
Genomic Health Announces Presentation of First Prospective Outcomes Study of Oncotype DX® Breast... Dec 10 2014
Genomic Health Advances Development of Novel Liquid Biopsy-Based Cancer Tests Dec 09 2014
Genomic Health Advances Development of Novel Liquid Biopsy-Based Cancer Tests Dec 09 2014
Genomic Health's Oncotype DX: Cancer Testing Made Easier Dec 04 2014
Genomic Health (GHDX) Downgraded From Hold to Sell Dec 03 2014
Oncotype DX® Predicts Outcomes in Prostate Cancer Patients, Significantly Changes Treatment... Dec 03 2014
Oncotype DX® Predicts Outcomes in Prostate Cancer Patients, Significantly Changes Treatment... Dec 03 2014
2014 San Antonio Breast Cancer Symposium to Feature Oncotype DX® DCIS Study in Press Program on... Dec 02 2014
Genomic Health to Present at the 26th Annual Piper Jaffray Healthcare Conference Nov 26 2014
Genomic Health to Present at the 26th Annual Piper Jaffray Healthcare Conference Nov 26 2014
Results from Second Oncotype DX® Prostate Cancer Test Clinical Validation and First Decision Impact... Nov 19 2014
Results from Second Oncotype DX® Prostate Cancer Test Clinical Validation and First Decision Impact... Nov 19 2014
GENOMIC HEALTH INC Financials Nov 14 2014
GENOMIC HEALTH INC Files SEC form 8-K, Change in Directors or Principal Officers Nov 10 2014
10-Q for Genomic Health, Inc. Nov 08 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK